Korean J Anesthesiol.  2013 Jun;64(6):517-523. 10.4097/kjae.2013.64.6.517.

Palonosetron has superior prophylactic antiemetic efficacy compared with ondansetron or ramosetron in high-risk patients undergoing laparoscopic surgery: a prospective, randomized, double-blinded study

Affiliations
  • 1Department of Anesthesiology and Pain Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
  • 2Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea. hkkil@yuhs.ac

Abstract

BACKGROUND
Postoperative nausea and vomiting (PONV) continues to be a major problem, because PONV is associated with delayed recovery and prolonged hospital stay. Although the PONV guidelines recommended the use of 5-hydroxy-tryptamine (5-HT3) receptor antagonists as the first-line prophylactic agents in patients categorized as high-risk, there are few studies comparing the efficacies of ondansetron, ramosetron, and palonosetron. The aim of present study was to compare the prophylactic antiemetic efficacies of three 5HT3 receptor antagonists in high-risk patients after laparoscopic surgery.
METHODS
In this prospective, randomized, double-blinded trial, 109 female nonsmokers scheduled for elective laparoscopic surgery were randomized to receive intravenous 4 mg ondansetron (n = 35), 0.3 mg ramosetron (n = 38), or 75 microg palonosetron (n = 36) before anesthesia. Fentanyl-based intravenous patient-controlled analgesia was administered for 48 h after surgery. Primary antiemetic efficacy variables were the incidence and severity of nausea, the frequency of emetic episodes during the first 48 h after surgery, and the need to use a rescue antiemetic medication.
RESULTS
The overall incidence of nausea/retching/vomiting was lower in the palonosetron (22.2%/11.1%/5.6%) than in the ondansetron (77.1%/48.6%/28.6%) and ramosetron (60.5%/28.9%/18.4%) groups. The rescue antiemetic therapy was required less frequently in the palonosetron group than the other groups (P < 0.001). Kaplan-Meier analysis showed that the order of prophylactic efficacy in delaying the interval to use of a rescue emetic was palonosetron, ramosetron, and ondansetron.
CONCLUSIONS
Single-dose palonosetron is the prophylactic antiemetics of choice in high-risk patients undergoing laparoscopic surgery.

Keyword

Ondansetron; Palonosetron; Postoperative nausea and vomiting; Prophylaxis; Ramosetron

MeSH Terms

Analgesia, Patient-Controlled
Anesthesia
Antiemetics
Benzimidazoles
Female
Humans
Incidence
Isoquinolines
Kaplan-Meier Estimate
Laparoscopy
Length of Stay
Nausea
Ondansetron
Postoperative Nausea and Vomiting
Prospective Studies
Quinuclidines
Antiemetics
Benzimidazoles
Isoquinolines
Ondansetron
Quinuclidines

Cited by  4 articles

Efficacy of Palonosetron vs. Ramosetron for the Prevention of Postoperative Nausea and Vomiting: A Meta-Analysis of Randomized Controlled Trials
Min-Soo Kim, Jin Ha Park, Yong Seon Choi, Sang Hun Park, Seokyung Shin
Yonsei Med J. 2017;58(4):848-858.    doi: 10.3349/ymj.2017.58.4.848.

Comparison of the efficacy of ramosetron and palonosetron for prevention of postoperative nausea and vomiting in patients undergoing gynecologic oncology surgery
Hea-Jo Yoon, Young Seok Jee, Young-deuk Kim
Anesth Pain Med. 2016;11(3):264-268.    doi: 10.17085/apm.2016.11.3.264.

Evaluation of the ability of continuous palonosetron infusion, using a patient-controlled analgesia device, to reduce postoperative nausea and vomiting
Ji Won Kang, Soo Kyoung Park
Korean J Anesthesiol. 2014;67(2):110-114.    doi: 10.4097/kjae.2014.67.2.110.

The effect of combination treatment using palonosetron and dexamethasone for the prevention of postoperative nausea and vomiting versus dexamethasone alone in women receiving intravenous patient-controlled analgesia
Seung-hwa Ryoo, Jae Hwa Yoo, Mun Gyu Kim, Ki Hoon Lee, Soon Im Kim
Korean J Anesthesiol. 2015;68(3):267-273.    doi: 10.4097/kjae.2015.68.3.267.

Full Text Links
  • KJAE
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr